| Lentivirus mediated pancreatic beta-cell-specific insulin gene therapy for STZ-induced diabetes F Erendor, YE Eksi, EO Sahin, MK Balci, TS Griffith, S Sanlioglu Molecular Therapy 29 (1), 149-161, 2021 | 19 | 2021 |
| Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation F Erendor, EO Sahin, AD Sanlioglu, MK Balci, TS Griffith, S Sanlioglu Gene therapy 28 (3), 130-141, 2021 | 17 | 2021 |
| Gene and cell therapy of human genetic diseases: Recent advances and future directions B Cetin, F Erendor, YE Eksi, AD Sanlioglu, S Sanlioglu Journal of Cellular and Molecular Medicine 28 (17), e70056, 2024 | 1 | 2024 |
| Microglia cells treated with synthetic vasoactive intestinal peptide or transduced with LentiVIP protect neuronal cells against degeneration AY Goksu, FG Kocanci, E Akinci, D Demir‐Dora, F Erendor, S Sanlioglu, ... European Journal of Neuroscience 59 (8), 1993-2015, 2024 | 1 | 2024 |
| Adenoviral vector design and construction for SARS-CoV-2 vaccine development EO Sahin, B Cetin, F Erendor, B Akkaya, AD Sanlioglu, S Sanlioglu HUMAN GENE THERAPY 32 (19-20), A101-A101, 2021 | | 2021 |
| Construction of a lentiviral vector-carrying SARS-CoV-2 spike gene for COVID-19 F Erendor, EO Sahin, B Akkaya, A Bisgin, DD Dora, S Koksoy, S Sanlioglu Mary Ann Liebert, 2021 | | 2021 |
| In vitro therapeutic evaluation of the lentiviral gene therapy vector encoding vasoactive intestinal peptide for retinal dystrophies B Akkaya, EO Sahin, F Erendor, AB Bilgin, S Ceylaner, S Sanlioglu HUMAN GENE THERAPY 32 (19-20), A72-A73, 2021 | | 2021 |
| Combined Efficacy of Insulin and Anti-Inflammatory Gene Therapies for Type 1 Diabetes Mellitus F Erendor, YE Eksi, EO Sahin, MK Balci, TS Griffith, S Sanlioglu MOLECULAR THERAPY 29 (4), 239-240, 2021 | | 2021 |
| Lentivirus mediated insulin promoter directed insulin gene expression is effective in suppressing postprandial glucose excursions in Type 1 diabetes YE Eksi, F Erendor, EO Sahin, MK Balci, S Sanlioglu HUMAN GENE THERAPY 30 (11), A154-A155, 2019 | | 2019 |
| New gene therapy modalities targeting oxidative stress and microglial activation are needed for effective treatment of retinitis pigmentosa EO Sahin, F Erendor, AB Bilgin, S Ceylaner, S Sanlioglu HUMAN GENE THERAPY 30 (11), A113-A113, 2019 | | 2019 |
| LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes F Erendor, EO Sahin, MK Balci, S Sanlioglu HUMAN GENE THERAPY 30 (11), A35-A36, 2019 | | 2019 |
| Tip 1 diyabetik deneklerde lentivirus aracılı vazoaktif intestinal peptit gen naklinin terapötik etkinliğinin belirlenmesi F Erendor Akdeniz Üniversitesi, 2019 | | 2019 |
| Generation of a Novel Gene Therapy Vector Encoding Beta-Cell–Specific Insulin for Diabetes Treatment EO Sahin, F Erendor, MK Balci, S Sanlioglu Diabetes 67 (Supplement_1), 2018 | | 2018 |
| Generation of a lentiviral vector encoding vasoactive intestinal peptide for type 1 diabetes F Erendor, EO Sahin, MK Balci, S Sanlioglu HUMAN GENE THERAPY 28 (12), A59-A60, 2017 | | 2017 |
| Multiple low-dose streptozotocin injections induced diabetes in Wistar rats characterised by insulitis and hyperglycaemia useful for gene transfer studies EO Sahin, F Erendor, MK Balci, S Sanlioglu HUMAN GENE THERAPY 28 (12), A49-A49, 2017 | | 2017 |
| Generation of a beta cell specific insulin gene therapy vector for diabetes EO Sahin, F Erendor, MK Balci, S Sanlioglu HUMAN GENE THERAPY 28 (12), A110-A110, 2017 | | 2017 |
